Back to top
more

Athersys, Inc. (ATHX)

(Delayed Data from NSDQ)

$1.55 USD

1.55
403,009

+0.04 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.55 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?

Investors in Athersys, Inc. (ATHX) need to pay close attention to the stock based on moves in the options market lately.

    Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage

    Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.

      Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

      At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.

        Ironwood, Allergan Report Positive Linzess IBS-C Study Data

        Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.

          Alexion Soliris Fails in Phase II/III Delayed Graft Function Study

          Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.

            Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

            Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

              Celgene (CELG) Otezla Approved in Japan for Two Indications

              Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.

                Roche Presents Positive Follicular Lymphoma Data on Gazvya

                Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.

                  Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

                  Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

                    Aimmune Closes Enrolment in Phase III Peanut Allergy Study

                    Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101

                      Foamix Completes Enrolment in Phase III Acne Drug Studies

                      Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies

                        Tirthankar Chakraborty headshot

                        New Strong Buy Stocks for November 14th

                        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday